Celon Pharma’s CPL’36 yields positive results in Phase 2 schizophrenia trial

3 Likes

Yeah, but does it make you fat?

1 Like

I asked bing AI:

does cpl’36 based on any other meds? does it work like 2nd generation aps or on muscarinic receptors like karxt?

It said:

  1. Mechanism of Action:
  • CPL’36 is a PDE10A inhibitor, which means it targets the phosphodiesterase 10A enzyme.
  • It is potentially a best-in-class second-generation molecule.
  • Unlike some other antipsychotics, CPL’36 does not directly interact with muscarinic receptors (like KARXT does).
  • Instead, it modulates the PDE10A pathway, which affects dopamine and other neurotransmitters in the brain.
  1. Features:
  • Favorable Safety Profile: Preclinical models show that CPL’36 doesn’t cause weight gain and has a lower metabolic risk compared to traditional antipsychotics.
  • Indications: It’s being investigated for schizophrenia and levodopa-induced dyskinesia in Parkinson’s disease (LiD).
  • Current Status: Phase 1 trials demonstrated safety and tolerability, and there are ongoing Phase 2 clinical trials (NCT05278156, NCT05297201).
  • Key Differentiating Factors: It’s a second-generation molecule, safe, and has potential procognitive effects.
  1. Comparison to Other PDE10A Inhibitors:

In summary, CPL’36 represents an exciting advancement in antipsychotic treatment, focusing on the PDE10A pathway without directly affecting muscarinic receptors

So it a second gen AP, it says no weight gain, but we’ll see…

1 Like

https://clinicaltrials.gov/study/NCT05278156
(No USA locations for this trial.) Looks promising.

2 Likes